When exogenous polysaccharide was added to the acapsular Cap67 cells we noted a decrease in Outcome I events possibly reflecting disaggregation of clumped cells as a consequence of increased surface charge [32].
For the measures PDSS total score, PDSS item 1, PDSS item 2, Ham-A, and Ham-D, all subjects, regardless of treatment group, demonstrated a significant decrease in outcome scores during the course of the study.
A second analysis was conducted to explore whether statin use was simply a marker for the 'healthy user effect' (implying that statin users were healthier than non-users at baseline thereby explaining the observed decrease in severe outcomes).
Assuming a probability of statin use of 0.17 and a 30 percent decrease in severe outcomes for influenza with statins, we estimated that a future case control study would require 637 cases and 2,548 controls to meet the standard criteria of 80 percent power.
In contrast, shorter mean sojourn times (lower limits reported in Table 1) were associated with a significant decrease in both outcomes (Table 6).
They have shown an increase in survival and a decrease in adverse outcomes when VT was set to 6 7 ml.kg−1 [ 28, 29].
Using 100 patients in each group with a yearly hospitalization/ED rate of 38.2%, we will be able to detect a 36.1% decrease in combined outcomes.
The observed decrease in cardiovascular outcomes seen with RR-bromocriptine in the 52-week trial may be the result of poor randomization.
For other outcomes, %-change values for the UC group are negative but considerably smaller in magnitude than for the PDC group (for example, unmet need – high baseline personal-care dependencies: UC group = −4.6% versus PDC group = −22.2%), meaning less of a decrease in adverse outcomes.
